Exagen inc. reports record q1 2025 revenue driven by growth in average selling price and testing volume

Carlsbad, calif., may 05, 2025 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended march 31, 2025, and recent corporate updates.
XGN Ratings Summary
XGN Quant Ranking